Combining caring with discovery, we AIM to get the right medicine to each patient. Discover how you, your loved one, or your patient may be eligible to participate.
COVID-19
Trial Locations: CA, NY & FL
This is an exploratory, randomized, placebo controlled, multi-center study to assess the pharmacokinetics and biomarkers of STAT-201 as a potential treatment to slow or halt the progression of SARS-CoV-2 infections from mild/moderate (stage 1-2A) to severe (stage 2B-3) in COVID-19 subjects as an adjunct to the clinical standard of care.
COVID-19 Long Hauler (PACSC)
Trial Locations: TBD
This is an interventional, phase II, randomized, placebo controlled, parallel assignment, single blind, multi-center study to assess safety and effectiveness of STAT-201 as a treatment to potentially mitigate the symptoms of post-acute SARS-CoV-2 infections.
Crohn's Disease Trial
Crohn's Disease
Trial Location: TBD
Statera’s lead investigational drug candidate, STAT-201, is being studied for the treatment of pediatric patients with Crohn’s disease, an inflammatory bowel disease that causes chronic inflammation of the gastrointestinal (or digestive) tract, causing symptoms such as persistent diarrhea, abdominal pain and rectal bleeding. Studies show that because the signs and symptoms of the disease are unpredictable, patients living with the disease endure significant burdens, not only physical, but also emotional and economic.
Statera completed a successful end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding a clinical development plan for a Phase 3 clinical trial evaluating STAT-201 in pediatric Crohn’s patients. Cytocom expects to begin enrolling patients by year-end 2021.
Please check back often as we will be implementing our notification and enrollment systems
Pancreatic Cancer Trial
Pancreatic Cancer
Trial Location: TBD
Statera’s STAT-401, an injectable pentapeptide is targeted for development as an adjunct to the standard of care to extend the duration of disease remission in patients with late-stage non-resectable pancreatic cancer. With recent FDA feedback regarding the clinical development program and establishing an advisory panel of oncology experts, Statera is is planning to initiate the clinical trial in the first half of 2022.
Please check back often as we will be implementing our notification and enrollment systems